What it's for (Indications)
- This ophthalmic combination preparation, containing dexamethasone and moxifloxacin, is indicated for the treatment of inflammatory conditions of the eye for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
- This includes conditions such as bacterial conjunctivitis, keratitis, and other anterior segment inflammations when susceptible bacterial species are present.
- It is particularly valuable in managing post-operative inflammation and preventing bacterial infection following ocular surgery, including cataract extraction.
- The anti-inflammatory action of dexamethasone helps alleviate pain, redness, and swelling, while moxifloxacin provides broad-spectrum antibacterial activity against common ocular pathogens.
- Clinical diagnosis of infection must be confirmed or strongly suspected, and sensitivity of the causative organism to moxifloxacin should be considered before initiation of therapy.
- Prolonged use should be avoided.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For ophthalmic use only. The typical dosage involves instilling one drop into the conjunctival sac of the affected eye(s) two to four times daily, or as directed by a healthcare professional. The frequency of application may be adjusted based on the severity of the inflammation and infection. It is crucial to taper the dosage gradually under medical supervision, especially when discontinuing treatment after prolonged use, to prevent rebound inflammation. The duration of treatment generally should not exceed 7 to 10 days due to the corticosteroid component, which can lead to adverse effects with extended application, such as elevated intraocular pressure and cataract formation. Patients should be advised not to discontinue treatment prematurely, even if symptoms improve, unless instructed by their ophthalmologist, to ensure complete eradication of infection. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with dexamethasone and moxifloxacin ophthalmic solution include transient ocular irritation, burning, stinging, and discomfort upon instillation.
- Other frequent adverse reactions may involve blurred vision, dry eye, increased lacrimation, and foreign body sensation.
- Prolonged use of the corticosteroid component, dexamethasone, carries significant risks such as elevation of intraocular pressure (IOP), which can potentially lead to glaucoma with optic nerve damage, and posterior subcapsular cataract formation.
- Secondary ocular infections (fungal, viral, or bacterial superinfections) are also a concern due to immune suppression.
- Less common but serious side effects can include corneal thinning, perforation, delayed wound healing, and allergic reactions.
- Systemic absorption leading to Cushing's syndrome or adrenal suppression is extremely rare with topical ophthalmic use but theoretically possible with very prolonged and frequent application.
- Patients should report any persistent or worsening symptoms to their physician promptly.
Serious Warnings
- Black Box Warning: **Serious Warnings Regarding Ocular Dexamethasone and Moxifloxacin Use:** While ophthalmic dexamethasone/moxifloxacin does not carry a formal FDA Black Box Warning, several serious risks warrant explicit and prominent attention. Prolonged use of the corticosteroid component, dexamethasone, can lead to a significant elevation of intraocular pressure (IOP), potentially resulting in optic nerve damage, visual field defects, and the formation of posterior subcapsular cataracts. Patients, especially those with a history of glaucoma or ocular hypertension, must undergo regular and careful IOP monitoring during treatment. Furthermore, the immunosuppressive effects of corticosteroids increase the risk of developing secondary ocular infections, including exacerbation of viral infections (especially herpes simplex keratitis), fungal infections, and bacterial superinfections with resistant organisms. In conditions that cause thinning of the cornea or sclera, the use of topical steroids may lead to perforation. Corticosteroids can also delay the healing process of corneal wounds or abrasions. Although rare with topical ophthalmic administration, systemic adverse reactions, including hypersensitivity reactions (e.g., anaphylaxis, Stevens-Johnson syndrome) potentially observed with systemic quinolones, cannot be entirely excluded. Close ophthalmologic supervision is imperative for all patients receiving this medication, and treatment duration should be strictly limited to the shortest effective period.
- This combination ophthalmic solution should be used with extreme caution and under close medical supervision.
- Prolonged use of corticosteroids in the eye, as found in this preparation, may lead to increased intraocular pressure (IOP) and the development of glaucoma, with potential damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation.
- Regular monitoring of IOP is essential, particularly in patients predisposed to glaucoma (e.
- g.
- , family history, high myopia, diabetes).
- Steroid use can also mask signs of infection and may enhance the establishment of secondary ocular infections due to fungi, viruses (including herpes simplex), or bacteria, especially if the infection is not properly treated with the antibiotic component.
- In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.
- Healing of corneal abrasions or surgical wounds may be delayed.
- Hypersensitivity reactions, ranging from localized ocular irritation to systemic manifestations, can occur.
- Patients should be advised against wearing contact lenses during treatment for ocular infection or inflammation.
How it Works (Mechanism of Action)
This ophthalmic preparation combines the potent anti-inflammatory effects of dexamethasone with the broad-spectrum bactericidal activity of moxifloxacin. Dexamethasone is a synthetic corticosteroid that exerts its anti-inflammatory action by inhibiting the release of arachidonic acid metabolites (prostaglandins and leukotrienes) through the induction of phospholipase A2 inhibitory proteins (lipocortins). It also stabilizes lysosomal membranes, reduces capillary permeability, and suppresses the migration of polymorphonuclear leukocytes, thereby diminishing inflammation, swelling, and pain. Moxifloxacin, a fourth-generation fluoroquinolone antibiotic, targets bacterial DNA replication and repair mechanisms. It acts by inhibiting two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. DNA gyrase is critical for unwinding and supercoiling bacterial DNA during replication, while topoisomerase IV is involved in chromosomal segregation of newly replicated bacterial DNA. By inhibiting these enzymes, moxifloxacin prevents bacterial growth and leads to bacterial cell death, providing bactericidal action against a wide range of gram-positive and gram-negative ocular pathogens. The combination addresses both infection and inflammation concurrently.